UCBJF:OTCMKTS
UCB SA
240,24 US$
arrow_upward
+1,82%(+4,30) 1K
15-okt, 16:00:00 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoUCBJF tikeri uchun statistika yaratilmoqda...
Ochish
240,24 US$
Yuqori
240,24 US$
Past
240,24 US$
Bozor kapitali
38,98 mlrd
Oʻrtacha hajm
139,00
Hajmi
10,00
52 haftalik eng yuqori
345,39 US$
52 haftalik eng past
219,60 US$
Beta
0,58
Muomaladagi aksiyalar
194,51 mln
Xodimlar soni
9 ming
Ochish
240,24 US$
Yuqori
240,24 US$
Past
240,24 US$
Bozor kapitali
38,98 mlrd
Oʻrtacha hajm
139,00
Hajmi
10,00
52 haftalik eng yuqori
345,39 US$
52 haftalik eng past
219,60 US$
Beta
0,58
Muomaladagi aksiyalar
194,51 mln
Xodimlar soni
9 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
ad-hoc-news.de
·
19 soat oldin
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
UCB SA haqida
CEOJean-Christophe Tellier
Xodimlar soni9 ming
Asos solingan18-yan, 1928
Bosh ofislar-
Sektor-
Veb-saytucb.com